Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Eyepoint Inc (EYPT)

Eyepoint Inc (EYPT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire - Mon Mar 16, 6:00AM CDT

WATERTOWN, Mass, March 16, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious...

EYPT : 12.38 (-3.51%)
EyePoint: Q4 Earnings Snapshot AP - Wed Mar 4, 6:23AM CST

EyePoint: Q4 Earnings Snapshot

EYPT : 12.38 (-3.51%)
EyePoint Reports Fourth Quarter and Full-Year 2025 Financial Results and Highlights Recent Corporate Developments GlobeNewswire - Wed Mar 4, 6:00AM CST

        – Both pivotal Phase 3 trials for DURAVYU in wet AMD on track for data readout beginning in mid-2026 – – Patients dosed in both COMO and CAPRI Phase 3 clinical trials for DURAVYU...

EYPT : 12.38 (-3.51%)
EyePoint Announces First Patients Dosed in Both Global Phase 3 Clinical Trials of DURAVYU™ for the Treatment of Diabetic Macular Edema GlobeNewswire - Mon Mar 2, 6:00AM CST

– Active Phase 3 programs for DURAVYU in wet AMD and DME, the two largest multi-billion-dollar retinal disease markets – – Topline data for DURAVYU in DME anticipated in 2H 2027 – WATERTOWN,...

EYPT : 12.38 (-3.51%)
EyePoint to Report Fourth Quarter and Full-Year 2025 Financial Results on March 4, 2026 GlobeNewswire - Wed Feb 25, 6:00AM CST

WATERTOWN, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with...

EYPT : 12.38 (-3.51%)
EyePoint Announces Participation at Upcoming Investor Conferences GlobeNewswire - Tue Feb 24, 6:00AM CST

WATERTOWN, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with...

EYPT : 12.38 (-3.51%)
EyePoint Appoints Michael Campbell as Chief Commercial Officer GlobeNewswire - Wed Feb 18, 6:00AM CST

– Seasoned commercial executive with over 30 years of leadership in retinal disease across biotech and large pharma – – Brings established track record of successful product launches and oversight...

EYPT : 12.38 (-3.51%)
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire - Tue Feb 17, 6:00AM CST

WATERTOWN, Mass., Feb. 17, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious...

EYPT : 12.38 (-3.51%)
EyePoint to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 GlobeNewswire - Thu Feb 5, 6:00AM CST

WATERTOWN, Mass., Feb. 05, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with...

EYPT : 12.38 (-3.51%)
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire - Fri Jan 16, 6:00AM CST

WATERTOWN, Mass., Jan. 16, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious...

EYPT : 12.38 (-3.51%)

Barchart Exclusives

Profit from Natural Resources with This 1 Stock Up 80% Barchart - 30 minutes ago
Glencore (GLNCY) has gained nearly 80% over the past 52 weeks. Shares maintain a Trend Seeker “Buy” signal and a 100% “Buy” opinion from Barchart. Fundamentals are attractive with 56% estimated earnings growth this year. Strong sentiment and analyst ratings support GLNCY here. Today’s Featured Stock Valued at $80.56 billion,... Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.